Hepatoblastoma – an institutional experience of this rare malignancy in children

Author:

Mehta Naimish N1,Solanki Sanket1,Kalra Manas1,Das Sri Aurobindo Prasad1,Sachdeva Anupam1,Nundy Samiran1

Affiliation:

1. Sir Ganga Ram Hospital

Abstract

Abstract Introduction: Hepatoblastoma is a common malignant liver tumour in children with a peak incidence in the first two years. Its previous mortality was reported to be 24%, but refinements in risk stratification, advances in chemotherapy and application of protocol-based therapy including surgery have resulted in improving long-term outcomes. Methods: We describe our experience of children with hepatoblastoma using the new treatment guidelines who underwent surgery between January 2013 and December 2020 Results: During the aforementioned period, 6 patients with hepatoblastoma (4 male and 2 female) were treated in our unit with median age at presentation being 15 (range 6 – 36) months. One patient was PRETEXT stage I, three were stage II and two were stage III. All of them had chemotherapy prior to surgical resection as per the SIOPEL-3 and SIOPEL-4 protocols varying between 2-4 cycles following which size reduction in the tumors was noted. right hepatectomy in three patients, non-anatomical hepatic resection in one, left lateral hepatectomy in one and left hepatectomy in one. The mean duration of surgery was 205 (range 115- 300) minutes and the mean blood loss was 50 (range 20-150) ml. There was no operative mortality following which all patients then had adjuvant chemotherapy and are alive with a median follow-up of 40.6 (18-104) months. Conclusion: The management of hepatoblastoma has changed significantly following the incorporation of recent updates from international groups into clinical practice. With the use of risk stratification, preoperative and adjuvant chemotherapy, and surgical excision, the overall and event-free survival has improved, reiterating the value of a multidisciplinary approach towards the treatment of this disease.

Publisher

Research Square Platform LLC

Reference27 articles.

1. Wiederkehr JC, Coelho IM, Avilla SG, Wiederkehr BA, Wiederkehr HA. Liver Tumors in Infancy. InHepatic Surgery 2013 Feb 13. IntechOpen.

2. Management of hepatoblastoma: an update: An update;Kremer N;Curr Opin Pediatr,2014

3. Predictors of survival and incidence of hepatoblastoma in the paediatric population;Allan BJ;HPB (Oxford),2013

4. Hepatoblastoma in an 11-year-old: Case report and a review of the literature;Pateva IB;Medicine (Baltimore),2017

5. The epidemiology of hepatoblastoma;Spector LG;Pediatr Blood Cancer,2012

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3